MGNX

MacroGenics, Inc.

5.32 USD
-0.02 (-0.37%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

MacroGenics, Inc. stock is up 18.22% since 30 days ago. The next earnings date is Aug 7, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 27.27% of the previous 10 July’s closed higher than June. In the last 8 Unusual Options Trades, there were 2 PUTs, 6 CALLs.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
03 Jun 13:41 21 Jun, 2024 10.00 PUT 2500 4735
03 Jun 13:42 19 Jul, 2024 5.00 CALL 813 1976
03 Jun 15:18 19 Jul, 2024 5.00 CALL 688 1976
05 Jun 15:35 21 Jun, 2024 5.00 CALL 910 659
17 Jun 15:59 20 Dec, 2024 10.00 CALL 500 37
15 Jul 16:46 19 Jul, 2024 5.00 CALL 1189 1889
22 Jul 14:56 19 Dec, 2025 5.00 CALL 200 236
23 Jul 18:47 20 Dec, 2024 5.50 PUT 236 0

About MacroGenics, Inc.

MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer. The company also develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4.